To assess the outcome and determine predictors of survival in pediatric patients with osteosarcoma of the extremities treated with a unified chemotherapy protocol at a single institution over a 15-year period.
We performed a retrospective analysis of medical records of 48 pediatric patients with histologically verified osteosarcoma of the extremities diagnosed at South Egypt Cancer Institute and received treatment between January 2001 and December 2015.
With a median follow-up of 61 months for the entire cohort, estimates of overall survival (OS) for 3- and 5-year were 50.9% and 42.1%, respectively. While the estimates of OS for 3- and 5-year in the nonmetastatic group were 79% and 65.2%, respectively. In the multivariable analysis, both metastatic disease at diagnosis and poor response to chemotherapy retained their statistical significance as independent predictors for event-free survival. Whereas for OS, a metastatic disease at diagnosis remained as the lone predictor of a dismal outcome, while a poor response to chemotherapy became marginally associated with an inferior outcome.
In Upper Egypt, whereas slightly less than two thirds of children with localized osteosarcoma of extremities survives their disease, metastasis at presentation remains the key predictor of dismal survival outcomes.
Departments of *Pediatric Oncology
††Medical Oncology, South Egypt Cancer Institute, Assiut University
Departments of †Clinical Oncology and Nuclear Medicine
¶Orthopedic Surgery and Traumatology, Faculty of Medicine, Assiut University, Assiut, Egypt
‡Department of Medical Oncology, King Faisal Specialist Hospital & Research Centre, Jeddah, Saudi Arabia
The authors declare no conflict of interest.
Reprints: Ahmed M. Morsy, MD, Pediatric Oncology Department, South Egypt Cancer Institute, El-methak Street, Assiut 71515, Egypt (e-mail: email@example.com).
Received October 15, 2018
Accepted December 9, 2018